Biovail Comments on Ultram ER Court Ruling

TORONTO--(Business Wire)--
Biovail Corporation (NYSE, TSX: BVF) announced today that on August 14, 2009, in
the United States District Court for the District of Delaware, Judge Kent A.
Jordan issued an opinion in favour of Par Pharmaceuticals, Inc. (Par) in the
patent-infringement litigation relating to Ultram ER (tramadol hydrochloride
extended-release tablets). Although Biovail is not a party to the action, the
decision could have an effect on Biovail`s revenues relating to Ultram ER.

The Court`s ruling, in conjunction with Par`s recent receipt of tentative
approval from the U.S. Food and Drug Administration (FDA) for its 100mg and
200mg strength tablets, could allow Par to launch their generic formulation of
those tablet strengths at any time. Biovail will be consulting with its partner,
Pricara (a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.) to determine
next steps. The decision as to whether or not to appeal the decision lies with
Purdue Pharma LP, the patent holder.

Biovail recorded Ultram ER revenues of $81.9 million in 2008, and $37.2 million
in the first half of 2009.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company engaged in the
formulation, clinical testing, registration, manufacture, and commercialization
of pharmaceutical products. The Company is focused on the development and
commercialization of medicines that address unmet medical needs in niche
specialty central nervous system (CNS) markets. For more information about
Biovail, visit the Company`s web site at www.biovail.com.

For further information, please contact Nelson F. Isabel at 905-286-3000 or send
inquiries to ir@biovail.com.

Biovail Corporation
Nelson F. Isabel, 905-286-3000
Vice-President, Investor Relations
& Corporate Communications

Copyright Business Wire 2009